Sanofi removed the interim tag from Brian Foard’s title as head of the specialty care global business unit (GBU) and added him to the company’s executive committee Tuesday morning.

Foard had served as interim head of the GBU since September 2023 in addition to his duties as head of specialty care North America and U.S. country lead. He joined the French drugmaker in 2017 as the global head of dermatology and respiratory, eventually being promoted to head of global immunology. 

Foard has been responsible for the launch of Dupixent, the eczema and asthma treatment jointly developed and commercialized by Sanofi and Regeneron, in more than 50 countries across numerous indications and age groups.

“I am very excited to have Brian join our Executive Committee. He is clearly one of our leaders who has been actively contributing to the success of our Play to Win strategy while embracing our culture and values,” Sanofi CEO Paul Hudson said in a statement. “His ability to motivate teams and inspire success across the globe is underpinned by his determination, strategic mindset and dedication to continue to transform Sanofi into a world leading immunology company. Brian’s best-in-class launch of Dupixent will help to set our roadmap for the first- and best-in-class molecules we are preparing to launch in the coming years.”

Sanofi made the personnel move just over a month after it laid out a dozen clinical-stage assets it labeled as “blockbuster” prospects. In an investor meeting towards the end of the year, Hudson said these treatments include nine innovative medicines and vaccines with peak sales potential between €2 and €5 billion, and referenced another three “pipeline-in-a-product” compounds with revenue capable of reaching over €5 billion.

Prior to joining Sanofi, he started his career at Galderma and then moved to Paris to serve as lead global marketing and launch readiness. While at that organization, he also served as GM for Australia and New Zealand as well as VP and GM of the global prescription business unit. 

“I am incredibly excited to take on this global role as Sanofi continues to drive innovation and deliver for patients,” Foard stated. “Under Paul’s leadership and his Play to Win strategy, Sanofi has set out on a course built for success and Specialty Care is at the core of the company’s ambitions. With this vision, and by doubling down on this work, we will continue to chase the miracles of science to improve people’s lives.”